Literature DB >> 11228365

Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine.

M L Garly1, C Balé, C L Martins, M Monteiro, E George, M Kidd, F Dias, P Aaby, H C Whittle.   

Abstract

In Guinea-Bissau, children were randomised at 6 months of age to receive either two doses of standard-titre measles vaccine at 6 and 9 months of age or an inactivated polio vaccine at 6 months and standard-titre measles vaccine at 9 months of age. During the first 5 months, children received Edmonston-Zagreb (EZ) vaccine and during the following 11 months, the Schwarz (SW) vaccine. Five percent of the mothers, 74% of children at 6 months of age, and 92% of unvaccinated children at 9 months of age had unprotective levels (<125 mIU/ml) of measles antibodies. Among children receiving EZ vaccine, 1% were unprotected at 18 months of age after either two (3/240) or one (3/211) doses of vaccine, the geometric mean measles antibody titre (GMT) being approximately 1550 mIU/ml in both groups. Among those receiving SW vaccine 9% (34/365) and 3% (9/310) were unprotected at 18 months of age in the two-dose and the one-dose groups (RR = 3.21 (95% confidence interval (CI) 1.56-6.58)), respectively. The GMT was higher after one dose of SW vaccine at 9 months of age (2491 mIU/ml) than after two doses of SW vaccine (1125 mIU) (P < 0.001). In the EZ vaccine group, there was no significant difference in antibody level for children vaccinated in the presence of high or low levels of maternal antibodies, whereas there was a marked difference in the SW group. The second EZ vaccine induced a significant antibody increase between 9 months of age (1191 mIU) and 18 months of age (1602 mIU, P=0.011), whereas antibody levels tended to decline from 9 months (1243 mIU) to 18 months of age (998 mIU, P = 0.124) after the second dose of SW vaccine. Conclusively, after two doses of EZ measles vaccine more children were protected at 18 months of age than after two doses of SW. One dose of SW provided the highest antibody response, but a higher proportion of unprotected than one or two doses of EZ. The EZ vaccine was less sensitive to maternal antibodies, and able to increase the antibody response by revaccination, while the second SW vaccine resulted in an unchanged or lower antibody response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228365     DOI: 10.1016/s0264-410x(00)00431-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

3.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30

Review 4.  Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.

Authors:  Daniel E Velasquez; Umesh Parashar; Baoming Jiang
Journal:  Expert Rev Vaccines       Date:  2017-12-29       Impact factor: 5.217

5.  Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.

Authors:  Jainaba Njie-Jobe; Samuel Nyamweya; David J C Miles; Marianne van der Sande; Syed Zaman; Ebrima Touray; Safayet Hossin; Jane Adetifa; Melba Palmero; Sarah Burl; David Jeffries; Sarah Rowland-Jones; Katie Flanagan; Assan Jaye; Hilton Whittle
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

Review 6.  Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Authors:  Stefan Niewiesk
Journal:  Front Immunol       Date:  2014-09-16       Impact factor: 7.561

7.  Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules.

Authors:  Ashley L Fowlkes; Desiree Witte; Judy Beeler; Susette A Audet; Robin Broadhead; William J Bellini; Felicity Cutts; Rita F Helfand
Journal:  Vaccine       Date:  2016-02-09       Impact factor: 3.641

8.  Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.

Authors:  Cesário L Martins; May-Lill Garly; Carlito Balé; Amabelia Rodrigues; Henrik Ravn; Hilton C Whittle; Ida M Lisse; Peter Aaby
Journal:  BMJ       Date:  2008-07-24

9.  Factors affecting the infant antibody response to measles immunisation in Entebbe-Uganda.

Authors:  Dennison Kizito; Robert Tweyongyere; Alice Namatovu; Emily L Webb; Lawrence Muhangi; Swaib A Lule; Henry Bukenya; Stephen Cose; Alison M Elliott
Journal:  BMC Public Health       Date:  2013-07-01       Impact factor: 3.295

10.  A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions.

Authors:  Cesario L Martins; Christine S Benn; Andreas Andersen; Carlito Balé; Frederik Schaltz-Buchholzer; Vu An Do; Amabelia Rodrigues; Peter Aaby; Henrik Ravn; Hilton Whittle; May-Lill Garly
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.